Ivacaftor/tezacaftor/elexacaftor (combination with ivacaftor; cystic fibrosis; ≥ 2 years, at least 1 non-Class I mutation, including gating mutation, excluding F508del mutation); Benefit assessment according to §35a SGB V

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen 2026 Open access

Read full text
Authors: Institute for Quality and Efficiency in Health Care
DOI: 10.60584/a25-62_en
Cited by: 0

Fields of Study & Subjects

Cystic Fibrosis Research Advances Pharmacogenetics and Drug Metabolism Inhalation and Respiratory Drug Delivery

Publication details

Journal / source
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Publication date
30 January 2026
Language
EN